Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 3 Nine cases of PMLP immunohistochemical information

From: Collapsin response mediator protein 4 promotor methylation level as a potential predictor for diagnosing primary malignant lymphoma of the prostate

  Surgical procedures Pathological types Immunophenotype
1 TURP DLBCL CK(−), LCA(+), CD45RO(−), CD20(+), CD79a(+), CyclinD1(−), CD10(−), MUM1(+), Bcl2(+), Bcl6(+), CD30(−), Ki-67(70% +)
2 TURP DLBCL CK(−), LCA(+), CD3(−), CD20(+), CD79a(+), CD5(−), CyclinD1(−), CD10(−), MUM1(+), Bcl2(+), Bcl6(+), Ki-67(55% +)
3 LRP DLBCL CK(−), LCA(+), CD3(−), CD45RO(−), CD20(+), CD79a(+), CyclinD1(−), CD10(+), CD30(−), Ki-67(40%)
4 TURP MCL CK(−), LCA(+), CD3(−), CD20(+), CD79a(+), CD5(+), CyclinD1(+), CD10(−), MUM1(+), Bcl2(+), Bcl6(−), CD30(−), Ki-67(30%)
5 LRP DLBCL CK(−), LCA(+), CD3(−), CD20(−), CD79a(+), CD5(−), CyclinD1(−), CD10(−), MUM1(−), Bcl2(+), Bcl6(+), CD30(−), Ki-67(90% +)
6 TURP DLBCL CK(−), LCA(+), CD45RO(−), CD20(+), CD79a(+), CD5(−), CyclinD1(−), CD10(−), MUM1(+), Bcl2(+), Ki-67(80% +)
7 TURP DLBCL CK(−), LCA(+), CD45RO(−), CD20(+), CD79a(+), CyclinD1(−), CD10(+), MUM1(−), Bcl2(+), Ki-67(80% +)
8 LRP DLBCL CK(−), LCA(+), CD45RO(−), CD20(−), CD79a(+), CD5(−), CyclinD1(−), CD10(+), MUM1(−), Bcl2(+), Bcl6(+), Ki-67(45% +)
9 TURP DLBCL CK(−), LCA(+), CD3(−), CD20(+), CD79a(+), CD5(−), CyclinD1(−), CD10(−), MUM1(−), Bcl2(+), Bcl6(+), CD30(−), Ki-67(80% +)
10 LRP DLBCL CK(−), LCA(+), CD45RO(−), CD20(−), CD79a(+), CD5(−), CyclinD1(−), CD10(−), MUM1(+), Bcl2(+), Bcl6(−), Ki-67(35% +)